Its new home in the Lion City will support the Asia Pacific (APAC) region, which accounts for 30% of all global pharmaceutical spending1 Cambridge, UK – April 27, 2022 – Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator working together with life scientists to advance research and enable faster breakthroughs, officially opens its newest regional hub in Singapore today.... Read more
2 August 2021, Cambridge, UK – Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for... Read more
Cambridge, UK and Shanghai, China, 12 April : Today Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDxTranslational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key... Read more
Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSureTM Opportunity to combine Expedeon and Abcam’s technologies to create new products to support research and diagnostic development Cambridge, UK, -06 January 2020: Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon’s Proteomics... Read more
Acquisition of leading protein conjugation technologies and products with wellknown industry brands, including Lightning-Link® and CaptSureTM Complementary to Abcam’s existing antibody and multiplex growth strategy, with high customer overlap Acquisition expected to be accretive from the first full year of ownership (FY21)1 and to deliver a ROIC (pretax) ahead of the Group’s WACC by the... Read more
BrickBio’s technology enables efficient placement of unnatural amino acids into recombinant antibodies at specific sites Together, the organizations will industrialize the technology to serve both the research and diagnostic markets CAMBRIDGE, UK and BOSTON, MA, USA, November 08, 2019 / B3C newswire / — Abcam plc, a global innovator in life science reagents and tools, is today pleased... Read more
Largest off-the-shelf diploid KO library, over 2,800 cell lines Cambridge, UK and Beijing, CN: 16 July, 2019 – Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the acquisition of the entire live cell line and lysates portfolio of EdiGene Inc, a leading company focused on developing genome editing... Read more
New tissue clearing kits and reagents for faster, accurate 3D imagingAbcam’s tissue clearing kits and reagents enable easy and rapid clearing for 3D imaging of tissues and cell culture models. Traditionally, 3D imaging of thick tissue sections and 3D cell culture models (organoids, microtissues, spheroids) has presented many technical challenges, including laborious and time-consuming tissue processing, layer-by-layer... Read more
— Abcam to Develop Conjugated FFPE IHC Validated Antibodies Compatible with the GeoMx DSP — SEATTLE and CAMBRIDGE, UK, April 01, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a commercial agreement with Abcam plc (AIM:ABC), a global innovator in life science reagents and tools, for the manufacture... Read more
New Jersey, USA and Cambridge, UK, – 25 March 2019: : Abcam, a global innovator in life science reagents and tools, and Visikol, a contract research organisation focused on advancing drug discovery, have announced a collaboration to develop new reagents and kits for improved tissue clearing and 3D imaging. Tissue clearing methods, which are essential to... Read more